Pfizer CEO commits to spend £330 million on Cambridge site even if they take over AstraZeneca. A new commitment. #fb
The Cambridge company at the heart of an international take over row is warning uncertainty over its future could interfere with research.
This morning Pfizer has "gone hostile", not with a renewed bid but with an appeal made directly to the shareholders of AstraZeneca.